A somewhat confusing victory for Allergan Inc. was won on June 18th, as the Honourable Justice Hughes upheld their patent on COMBIGAN despite the fact
In a move with far reaching implications for the debates around pharmaceutical patents, innovation and access to medicines, the Indian patent office issued its first
On January 21, the WHO 130th WHO Executive Board (EB) adopted a resolution for agenda item 6.13 “substandard/spurious/falsely-labelled/falsified/counterfeit medical products” [SFFC]. The resolution is intended
Dan Whalen is a JD Candidate at Osgoode Hall Law School Bayer was dealt a blow when the Federal Court of Appeal upheld the decision
On Friday, July 31st, the United States House Committee on Energy and Commerce approved “America’s Affordable Health Choices Act” by a narrow three-vote margin. The
The Federal Court of Appeal has recently released its first decision interpreting Section 8 of the Patented Medicines (Notice of Compliance) Regulations [PM(NOC)]. The PM(NOC)
